Clinical Trials Logo

Hypersensitivity Pneumonitis clinical trials

View clinical trials related to Hypersensitivity Pneumonitis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05723796 Completed - Clinical trials for Hypersensitivity Pneumonitis

Study of Nasal Mucosa Histopathological Changes in Chronic Hypersensitivity Pneumonitis

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Background:Hypersensitivity pneumonitis (HP) is an interstitial lung disease that develops after inhalation of organic or inorganic antigens in susceptible individuals. The nasal mucosa is constantly exposed to these antigens that can irritate the respiratory mucosa. Objectives: to assess the burden of sinonasal symptoms in HP patients and to evaluate the nasal histopathology in those patients.

NCT ID: NCT05458635 Completed - Clinical trials for Pulmonary Hypertension

Predictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Hypersensitivity pneumonitis (HP) is a complex immune mediated disorders caused by repeated inhalation of and sensitization to wide range of antigens including organic particles and chemical compounds, leading to exaggerated immuneresponse. Hypersenstivity pneumonitis is a common form of diffuse parenchymal lung diseases in Egypt .Pulmonary hypertension has been found as a complication of a number of diseases affecting the lung interstitium, including hypersensitivity pneumonitis, with subsequent affection of the life expectancy Rationale of the study: to find predictors for the development of pulmonary hypertension in patients with hypersensitivity pneumonitis

NCT ID: NCT04675619 Completed - Clinical trials for Hypersensitivity Pneumonitis

Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis

Start date: December 1, 2019
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. This study included 40 adult patients (≥ 18 years) with a diagnosis of chronic progressive hypersensitivity pneumonitis. The included patients were divided into 2 groups 20 patients in each one. Group 1: will receive pirfenidone in addition to the conventional treatment Group 2: will be maintained on conventional treatment. Forced vital capacity (FVC),6 minutes walking test(6MWT), oxygen tension in the arterial blood (PaO2), and St. George's Respiratory Questionnaire (SGRQ ) were measured before and after 6 months of a pirfenidone treatment trial. Results

NCT ID: NCT04273867 Completed - Clinical trials for Interstitial Lung Disease

Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis

CHP-HRQOL
Start date: July 10, 2020
Phase:
Study type: Observational

The objective of this study is to administer and validate a disease specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP).

NCT ID: NCT03873649 Completed - Clinical trials for Hypersensitivity Pneumonitis

Immune Response in Hypersensitivity Pneumonitis

Start date: November 29, 2018
Phase:
Study type: Observational

Hypersensitivity pneumonitis (HP) is an inflammatory lung disease that is caused by exposure of susceptible individuals to organic materials in the environment. It is also known by various names depending on the exposure and some of these names include farmer's lung, pigeon breeder's lung, hot tub lung to name a few. HP can cause lung scarring that impairs breathing and oxygenation. Early detection and avoidance of triggers can stop and reverse the disease but a significant number of patients continue to have active disease requiring treatment in spite of avoiding the trigger. The current choice of therapies is based on clinical experience and not on rigorous clinical trials. Not fully understanding the type of inflammation that is seen in HP and the cells involved in this inflammatory response limits health care providers' ability to choose drugs to study in HP that can stop the inflammation and limit scar formation. The goal of the investigators' study is to better understand the type of cells that are involved in the inflammatory response in the lungs of HP patients and what drives these cells to be active. By better understanding the type of cells and what drives them, health care providers can begin to choose and study drugs that can limit the inflammation and subsequent scarring. The investigators' will recruit HP patients and with their consent perform a scope of the lungs (bronchoscopy) with a limited lung wash to get the inflamed cells out of the lungs to further study them in the lab. The investigators' study will provide us with preliminary results to guide us in performing a more detailed study in the future to better understand the disease.

NCT ID: NCT02523833 Completed - Clinical trials for Hypersensitivity Pneumonitis

Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis

Start date: September 1, 2015
Phase: N/A
Study type: Interventional

Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation in which lung inflammation is caused by inhalation of specific organic antigens or low molecular weight particles in previously sensitized individuals. Systemic symptoms may or may not be present. Chronic HP represents the final stage of the disease, caused by prolonged exposure to a particular antigen, leading to pulmonary fibrosis. In chronic HP, pulmonary function tests (PFTs) commonly present a restrictive ventilatory pattern, with decreased diffusion of carbon monoxide (DLCO). Some patients can also have obstructive disorders with expiratory flow limitation, due to obstruction of the small airways typically caused by bronchiolar involvement in this pathology. However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. First, conventional PFTs may be normal in patients with small airway involvement, since they contribute to less than 30% of the total airway resistance. In addition, damage to the small airways in HP is generally occurring parallel to areas of focal fibrosis - even when small airways are involved, these regions can be completely ignored, since they are excluded from ventilation. In summary, traditional PFTs are not sufficiently sensitive to detect diffuse small airway involvement in these diseases. In these cases, other functional tests, such as forced oscillation technique (FOT) and high resolution computer tomography (HRCT) scans of the chest with expired studies, could be used for this purpose. This will be a cross-sectional study, which will include the following evaluations in 28 patients with HP recruited from our clinic: - Clinical variables: (A) demographic and anthropometric data; (B) Clinical data: Onset of symptoms and time of diagnosis C) Dyspnea score: D) Smoking: * Current or former smoker * Smoking history (number of cigarettes smoked per day and for how long); - Spirometry with forced and slow maneuvers before and after bronchodilator (salbutamol); - Plethysmography to measure lung volumes; - Diffusion capacity of carbon monoxide (DLCO); - High-resolution chest CT with expiratory scans; - Six-minute walk test; - Cardio-respiratory test using a maximal incremental treadmill. - Forced oscillation technique (FOT).

NCT ID: NCT01487850 Completed - Clinical trials for Hypersensitivity Pneumonitis

Wind Instruments' Fungal Contamination

Start date: May 2007
Phase: N/A
Study type: Interventional

On the basis of 2 cases of immunologically-induced lung disease in 2 saxophonists, the investigators supposed that wind reed instruments could be contaminated with molds. The investigators led a study on 40 musicians playing a wind reed instrument to analyze instruments' fungal contamination and its immunological and clinical consequences for musicians.